Clinical Trial

An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)

Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The primary purpose of the study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PAH from studies INS1009-201 (NCT04791514), INS1009-202 (NCT05147805) and other lead-in studies of TPIP in participants with PAH.
Protocol Amendment History 38 amendments
This ClinicalTrials.gov record has been amended 38 times since 2022-12-06; most recent amendment 2026-07-06.
Status change: Recruiting → Active, Not Recruiting 2025-04-23
Status change: Not Yet Recruiting → Recruiting 2023-03-03
Trial Details
NCT Number NCT05649748
Lead Sponsor Insmed Incorporated
Conditions Pulmonary Arterial Hypertension
Enrollment 91 participants
Start Date 2023-03-07
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-08